Vetter is a Winner of the AbbVie TRIUMPH AWARD
News May 12, 2016
AbbVie has awarded Vetter the TRIUMPH AWARD for 2015. The award was granted for meeting AbbVie’s ‘predetermined high-level demands of service’. Vetter received this prestigious award as a contract manufacturer in the category Third-Party Manufacturers - Supplier of the Year. Recently, Vetter announced that the company won two other coveted awards, the WorldStar Award 2016 for its syringe closure system Vetter-Ject®, and the 2016 CMO Leadership Award in four categories including, quality, capabilities, expertise, and compatibility.
The AbbVie TRIUMPH AWARD was created to acknowledge contract service companies whose efforts are ‘well-aligned with the company’s business strategy, and make an important contribution to AbbVie’s strategic vision on a long-term basis’. With this award, granted within a field of more than one thousand contractors, the company recognizes its top performing contract suppliers for efforts that consistently add measureable value, and regularly exceed best-in-class performance on behalf of AbbVie and patients who come to rely on their products.
Vetter received this prestigious award as a contract manufacturer for 2015 in the category Third-Party Manufacturers - Supplier of the Year. This recognition was achieved by meeting the predetermined high-level demands of service AbbVie has come to expect that is ‘consistently above-average’. “The winning of this award is especially significant for Vetter as it recognizes our continuing efforts to provide our customers a high-level of service, and it is particularly gratifying since it is from one of the world’s leading biopharmaceutical companies,” said Vetter Managing Director Peter Soelkner.
“This award is a reflection of the value that Vetter brings to the biopharmaceutical industry, and consequently to patients worldwide, and is yet another affirmation that Vetter continues to exceed the expectations of our peers in areas of critical importance to their business.” In a speech honoring Vetter for the award, AbbVie highlighted the importance of the good partnership it has forged with Vetter, specifically noting the achievement of a high number of commercial batches, as well as the many project activities performed on the company’s behalf.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018